Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul;26(28):2100563.
doi: 10.2807/1560-7917.ES.2021.26.28.2100563.

Efficacy and effectiveness of COVID-19 vaccines against SARS-CoV-2 infection: interim results of a living systematic review, 1 January to 14 May 2021

Thomas Harder  1 , Judith Koch  1 , Sabine Vygen-Bonnet  1 , Wiebe Külper-Schiek  1 , Antonia Pilic  1 , Sarah Reda  1 , Stefan Scholz  1 , Ole Wichmann  1
Affiliations

Efficacy and effectiveness of COVID-19 vaccines against SARS-CoV-2 infection: interim results of a living systematic review, 1 January to 14 May 2021

Thomas Harder et al. Euro Surveill. 2021 Jul.

Abstract

Evidence on COVID-19 vaccine efficacy/effectiveness (VE) in preventing asymptomatic SARS-CoV-2 infections is needed to guide public health recommendations for vaccinated people. We report interim results of a living systematic review. We identified a total of 30 studies that investigated VE against symptomatic and/or asymptomatic infection. In fully vaccinated individuals, VE against symptomatic and asymptomatic infections was 80-90% in nearly all studies. Fully vaccinated persons are less likely to become infected and contribute to transmission.

Keywords: COVID-19; SARS-CoV-2; systematic review; vaccination; vaccine effectiveness.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: None declared.

Figures

Figure
Figure
PRISMA flowchart of the living systematic review on efficacy and effectiveness of COVID-19 vaccines against SARS-CoV-2 infection
See this image and copyright information in PMC

Comment in

References

    1. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. 10.1136/bmj.l4898 - DOI - PubMed
    1. Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919. 10.1136/bmj.i4919 - DOI - PMC - PubMed
    1. Amit S, Regev-Yochay G, Afek A, Kreiss Y, Leshem E. Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients. Lancet. 2021;397(10277):875-7. 10.1016/S0140-6736(21)00448-7 - DOI - PMC - PubMed
    1. Andrejko K, Pry J, Myers JF, Jewell NP, Openshaw J, Watt J, et al. Early evidence of COVID-19 vaccine effectiveness within the general population of California. medRxiv. 2021.04.08.21255135. 10.1101/2021.04.08.21255135 - DOI
    1. Britton A, Jacobs Slifka KM, Edens C, Nanduri SA, Bart SM, Shang N, et al. Effectiveness of the Pfizer-BioNTech COVID-19 vaccine among residents of two skilled nursing facilities experiencing COVID-19 outbreaks—Connecticut, December 2020–February 2021. MMWR Morb Mortal Wkly Rep. 2021;70(11):396-401. 10.15585/mmwr.mm7011e3 - DOI - PMC - PubMed

Publication types

Substances